Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.50 |
| ▸ | BRD4 | O60885 | 12/20 | 0.47 |
| ▸ | BRD9 | Q9H8M2 | 9/20 | 0.47 |
| ▸ | BRD7 | Q9NPI1 | 6/20 | 0.47 |
| ▸ | BRD2 | P25440 | 1/20 | 0.47 |
| ▸ | TAF1 | P21675 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.43 |
| ▸ | BPTF | Q12830 | 1/20 | 0.43 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | ATAD2B | Q9ULI0 | 1/20 | 0.43 |
| ▸ | ESRRA | P11474 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31655705 | 1.00 | ERN1 (0.50) | ERN1BRD4BRD9BRD7BRD2 | |
| SCHEMBL23783301 | 0.85 | BRD4 (0.47) | ERN1BRD4BRD9BRD7BRD2 | |
| SCHEMBL30032468 | 0.85 | BRD4 (0.47) | ERN1BRD4BRD9BRD7BRD2 | |
| SCHEMBL30032023 | 0.85 | BRD4 (0.64) | BRD4BRD9BRD7BRD2 | |
| SCHEMBL23783259 | 0.85 | BRD4 (0.64) | BRD4BRD9BRD7BRD2 | |
| SCHEMBL23783384 | 0.82 | BRD4 (0.58) | BRD4BRD9BRD7BRD2TAF1 | |
| SCHEMBL21224797 | 0.80 | BRD9 (0.67) | ERN1BRD4BRD9BRD7BRD2 | |
| SCHEMBL23798124 | 0.78 | BRD4 (0.57) | BRD4BRD9BRD7BRD2TAF1 | |
| SCHEMBL30032371 | 0.78 | BRD4 (0.57) | BRD4BRD9BRD7BRD2TAF1 | |
| SCHEMBL30683000 | 0.77 | BRD4 (0.44) | ERN1BRD4BRD9BRD7BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008778-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12351579-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240002382-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-04 | — | — | US | disclosed |
| US-20230416246-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230066136-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230066136-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-11560381-B1 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11560381-B1 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11414416-B1 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2022-08-16 | — | — | US | disclosed |
| EP-3917517-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020160198-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160198-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416246-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | ERN1 1459/4885BRD4 42/4885BRD9 290/4885 |
| US-20230066136-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | ERN1 1459/4885BRD4 42/4885BRD9 290/4885 |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | ERN1 1459/4885BRD4 42/4885BRD9 290/4885 |
| US-20240002382-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | ERN1 1459/4885BRD4 42/4885BRD9 290/4885 |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | ERN1 1459/4885BRD4 42/4885BRD9 290/4885 |
| US-11414416-B1 | Compounds and uses thereof | VHL, TFEB, BECN1 | ERN1 1459/4885BRD4 42/4885BRD9 290/4885 |
| US-11560381-B1 | Compounds and uses thereof | VHL, TFEB, BECN1 | ERN1 1459/4885BRD4 42/4885BRD9 290/4885 |
| US-20260008778-A1 | COMPOUNDS AND USES THEREOF | BRD9, BCL9L, BCL9 | ERN1 540/4885BRD4 127/4885BRD9 1/4885 |
| US-12351579-B2 | Compounds and uses thereof | VHL, TFEB, BECN1 | ERN1 1459/4885BRD4 42/4885BRD9 290/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | ERN1 1459/4885BRD4 42/4885BRD9 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.